AT7867

• Description :

  AT7867 is a potent ATP-competitive inhibitor of Akt1/Akt2/Akt3 and p70S6K/PKA with IC50s of 32 nM/17 nM/47 nM and 85 nM/20 nM, respectively.

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Akt; PKA; Ribosomal S6 Kinase (RSK)

• Type :

  Reference compound

• Related Pathways :

  MAPK/ERK Pathway; PI3K/Akt/mTOR; Stem Cell/Wnt; TGF-beta/Smad

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/AT7867.html

• Concentration :

  10mM

• Purity :

  99.85

• Solubility :

  DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  ClC1=CC=C(C=C1)C2(CCNCC2)C3=CC=C(C=C3)C4=CNN=C4

• Molecular Formula :

  C20H20ClN3

• Molecular Weight :

  337.85

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Grimshaw KM, et al. AT7867 is a potent and oral inhibitor of AKT and p70 S6 kinase that induces pharmacodynamic changes and inhibits human tumor xenograft growth. Mol Cancer Ther, 2010, 9 (5), 1100-1110.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  Akt1; Akt2; Akt3; p70S6K; PKA

• CAS Number :

  [857531-00-1]